Despite extensive adjustment for severity of diabetes at baseline and presence of major mortality risk factors, the risk of death observed in diabetic subjects treated with insulin may be due to an indication bias, i.e. may be related to differences in the severity of diabetes, with cases probably more severe in subjects treated with insulin than in those treated with non-insulin agents (metformin or sulfonylureas). The gene discussed is INS; the disease is diabetes mellitus.